Posted by Michael Wonder on 31 May 2024
NH TherAguix receives FDA fast track designation for AGuIX, its novel radio-enhancer in the treatment of malignant gliomas, and provides an update on its developments and prospects
30 May 2024 - Key regulatory milestone confirming the interest of the US authorities in AGuIX, a next generation nanodrug developed by NH TherAguix to improve tumour targeting and increase local radiobiological damage in tumour tissue by amplifying irradiation signal.
NH TherAguix today announced that its lead drug candidate, AGuIX, has received fast track designation from the US FDA as a next-generation radio-enhancer for the treatment of malignant gliomas, and in particular glioblastoma, the most common and deadliest brain cancer globally.
